The Down Under medical landscape is excited with the introduction of retatrutide, a innovative dual GIP and GLP-1 receptor agonist showing significant results in early trials for managing obesity. This https://veriea.com/2026/06/10/retatrutide-australia-the-next-generation-in-weight-loss/